Skip to main content

Leukaemia: Drugs

Question for Department of Health

UIN 7658, tabled on 16 July 2015

To ask the Secretary of State for Health, what steps his Department is taking to ensure that patients with chronic myeloid leukaemia in England have access to (a) Ponatinib and (b) other innovative new medicines.

Answered on

21 July 2015

A number of drugs for the treatment of chronic myeloid leukaemia have been recommended by the National Institute for Health and Care Excellence and are routinely available in England.

A number of other drugs, including ponatinib, are available through the Cancer Drugs Fund.

We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.